In:
British Journal of Nutrition, Cambridge University Press (CUP), Vol. 122, No. 6 ( 2019-09-28), p. 698-706
Abstract:
As only limited evidence is available for potential benefits of n- 3 PUFA supplementation in patients with peripheral arterial disease (PAD), we studied the effects of 4 g n -3 PUFA on endothelial function and inflammatory markers. Seventy patients with stable PAD classified as Rutherford stage 2 or 3 and good control of cardiovascular factors were randomised to receive either 4 g n -3 PUFA or placebo daily for 3 months in a double-blind fashion. Primary endpoint was endothelial function assessed by flow-mediated vasodilation (FMD). In addition, ankle–brachial index, maximum and pain-free walking distances were determined. Lipid parameters including the omega-3 index reflecting n -3 PUFA intake as well as pro-inflammatory, endothelial and platelet activation markers were measured over the same time interval. After 3 months of treatment with 4 g n -3 PUFA daily, a significant improvement of FMD was observed compared with placebo ( n -3 PUFA, median Δ 3·7 (interquartile range (IQR) –1·8, 7·1) % v . placebo, Δ –0·5 (IQR –6·5, 3·0) %, P = 0·01 between the groups). After a 3-month washout period, this benefit was not sustained ( n -3 PUFA, median Δ 0·6 (IQR –2·2, 5·6) % v . placebo, Δ –0·9 (IQR –6·6, 6·7) %, P = 0·20). In response to n -3 PUFA, an improvement of lipid parameters with a pronounced increase in the omega-3 index was seen. No changes were found for other parameters. In conclusion, in patients with PAD, 4 g/d n -3 PUFA improved cardiovascular risk in PAD patients, which needs testing in large-scale trials.
Type of Medium:
Online Resource
ISSN:
0007-1145
,
1475-2662
DOI:
10.1017/S0007114519001582
Language:
English
Publisher:
Cambridge University Press (CUP)
Publication Date:
2019
detail.hit.zdb_id:
2016047-1
SSG:
12
SSG:
21
Permalink